JP2022177119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022177119A5 JP2022177119A5 JP2022144243A JP2022144243A JP2022177119A5 JP 2022177119 A5 JP2022177119 A5 JP 2022177119A5 JP 2022144243 A JP2022144243 A JP 2022144243A JP 2022144243 A JP2022144243 A JP 2022144243A JP 2022177119 A5 JP2022177119 A5 JP 2022177119A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- administration
- drug
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- FWZAWAUZXYCBKZ-NSHDSACASA-N 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide Chemical compound COc1ccc(F)cc1C(=O)NCc1ccc(cc1)-c1nn([C@@H](C)C(F)(F)F)c(N)c1C(N)=O FWZAWAUZXYCBKZ-NSHDSACASA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 231100000402 unacceptable toxicity Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025044178A JP2025098099A (ja) | 2019-12-06 | 2025-03-19 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944674P | 2019-12-06 | 2019-12-06 | |
| US62/944,674 | 2019-12-06 | ||
| US202063077996P | 2020-09-14 | 2020-09-14 | |
| US63/077,996 | 2020-09-14 | ||
| US202063109698P | 2020-11-04 | 2020-11-04 | |
| US63/109,698 | 2020-11-04 | ||
| JP2021557408A JP7142173B2 (ja) | 2019-12-06 | 2020-12-03 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
| PCT/US2020/063089 WO2021113497A1 (en) | 2019-12-06 | 2020-12-03 | Dosing of a bruton's tyrosine kinase inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557408A Division JP7142173B2 (ja) | 2019-12-06 | 2020-12-03 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025044178A Division JP2025098099A (ja) | 2019-12-06 | 2025-03-19 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022177119A JP2022177119A (ja) | 2022-11-30 |
| JP2022177119A5 true JP2022177119A5 (enExample) | 2023-10-31 |
| JP7654604B2 JP7654604B2 (ja) | 2025-04-01 |
Family
ID=73854977
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557408A Active JP7142173B2 (ja) | 2019-12-06 | 2020-12-03 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
| JP2022144243A Active JP7654604B2 (ja) | 2019-12-06 | 2022-09-12 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
| JP2025044178A Pending JP2025098099A (ja) | 2019-12-06 | 2025-03-19 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557408A Active JP7142173B2 (ja) | 2019-12-06 | 2020-12-03 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025044178A Pending JP2025098099A (ja) | 2019-12-06 | 2025-03-19 | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230041515A1 (enExample) |
| EP (1) | EP4069219A1 (enExample) |
| JP (3) | JP7142173B2 (enExample) |
| KR (2) | KR20220100992A (enExample) |
| CN (1) | CN115175677A (enExample) |
| AU (2) | AU2020397034B2 (enExample) |
| BR (1) | BR112022009716A2 (enExample) |
| IL (1) | IL292882A (enExample) |
| MX (1) | MX2022006631A (enExample) |
| WO (1) | WO2021113497A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| KR20220100992A (ko) * | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55064A (fr) * | 2015-12-16 | 2021-09-29 | Loxo Oncology Inc | Composés utilisés comme inhibiteurs de kinase |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| KR102429704B1 (ko) | 2016-08-05 | 2022-08-04 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| CN110546151B (zh) | 2017-04-18 | 2023-04-28 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
| JP2020528061A (ja) | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法 |
| SG11202005985PA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| FI3788042T3 (fi) | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| KR20220100992A (ko) * | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
-
2020
- 2020-12-03 KR KR1020227022407A patent/KR20220100992A/ko not_active Ceased
- 2020-12-03 BR BR112022009716A patent/BR112022009716A2/pt unknown
- 2020-12-03 EP EP20825385.6A patent/EP4069219A1/en active Pending
- 2020-12-03 JP JP2021557408A patent/JP7142173B2/ja active Active
- 2020-12-03 AU AU2020397034A patent/AU2020397034B2/en active Active
- 2020-12-03 IL IL292882A patent/IL292882A/en unknown
- 2020-12-03 MX MX2022006631A patent/MX2022006631A/es unknown
- 2020-12-03 WO PCT/US2020/063089 patent/WO2021113497A1/en not_active Ceased
- 2020-12-03 US US17/782,758 patent/US20230041515A1/en active Pending
- 2020-12-03 CN CN202080095816.0A patent/CN115175677A/zh active Pending
- 2020-12-03 KR KR1020237028538A patent/KR20230127372A/ko active Pending
-
2022
- 2022-09-12 JP JP2022144243A patent/JP7654604B2/ja active Active
-
2024
- 2024-02-26 AU AU2024201263A patent/AU2024201263B2/en active Active
-
2025
- 2025-03-19 JP JP2025044178A patent/JP2025098099A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180461A5 (enExample) | ||
| JP6117845B2 (ja) | ニタゾキサニドの制御放出医薬配合物 | |
| JP2024074963A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2017222679A (ja) | 医薬組成物 | |
| JP2018507243A5 (enExample) | ||
| JP2022177119A5 (enExample) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2021504384A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2004525143A5 (enExample) | ||
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| BR112019026029A2 (pt) | Formulações farmacêuticas orais de remogliflozina | |
| JP2021503448A5 (enExample) | ||
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| RU2003100081A (ru) | Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии | |
| JPWO2023049920A5 (enExample) | ||
| US20190142786A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| US12168000B2 (en) | Methods of treating pain | |
| CN1537006A (zh) | 含有米尔塔扎平和对乙酰氨基酚或一种非甾类消炎药的用于治疗头痛的联合用药物 | |
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases |